NCT01822509 - Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 16, 2013

Primary Completion Date

December 31, 2018

Study Completion Date

June 10, 2021

Conditions

Allogeneic Hematopoietic Stem Cell Transplant RecipientMyeloproliferative NeoplasmRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid LeukemiaRecurrent Chronic Lymphocytic LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Hematologic MalignancyRecurrent Hodgkin LymphomaRecurrent Myelodysplastic SyndromeRecurrent Non-Hodgkin LymphomaRecurrent Plasma Cell Myeloma

Interventions

BIOLOGICAL

Ipilimumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (13)

30342

Northside Hospital, Atlanta

33607

Moffitt Cancer Center-International Plaza, Tampa

33612

Moffitt Cancer Center, Tampa

80218

Colorado Blood Cancer Institute, Denver

91010

City of Hope Comprehensive Cancer Center, Duarte

91030

City of Hope South Pasadena, South Pasadena

92093

UC San Diego Moores Cancer Center, La Jolla

04401

Eastern Maine Medical Center, Bangor

04412

Lafayette Family Cancer Center-EMMC, Brewer

02114

Massachusetts General Hospital Cancer Center, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

02129

Massachusetts General Hospital, Charlestown

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH